I-Mab in talks about deals, stake sale to build on $3B AbbVie alliance — Bloomberg
A year after I-Mab made headlines with its $2.9 billion deal licensing a CD47 drug to AbbVie, the Chinese biotech is reportedly holding early talks with global pharma players about partnerships and potential investment.
The Shanghai-based, Nasdaq-listed company is mulling “clinical and commercial cooperation in China and a potential equity stake sale,” Bloomberg reported, quoting people familiar with the matter. Both US and European drugmakers are among the suitors involved in preliminary discussions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.